Format

Send to

Choose Destination
Avicenna J Med Biotechnol. 2017 Oct-Dec;9(4):163-168.

Lactococcus lactis : A New Strategy for Vaccination.

Author information

1
Department of Microbiology, Arak branch, Islamic Azad University, Arak, Iran.
2
Razi Vaccine and Serum Research Institute, Arak Branch, Arak, Iran.
3
Department of Microbiology, Islamic Azad University, Arak Branch, Arak, Iran.

Abstract

Needle free vaccines have a several advantages and very attractive way for vaccination. In a body, mucosal surfaces provide a universal entry portal for all the known and emerging infectious pathogenic microbes. Therefore, it seems, vaccination strategies need to be reorganized for vaccines that are hindering the entry capability of pathogenic microbes through mucosal surfaces. Lactic acid Bacteria (LAB) are widely used in the food industry and at the present, used as delivery vehicles for biological investigations. In this review, we summarized the Results of several studies which Lactococcus lactis (L. lactis) used as a live vector for vaccines. These bacteria are considered as promising candidates for heterologous expression of proteins and biotechnological usage. LAB are considered as promising candidates for heterologous expression of proteins and biotechnological usage. The results showed that these bacteria have an ability to deliver antigen to immune system. Therefore, developing mucosal live vaccines using lactic acid bacterium, L. lactis, as an antigen delivery vector, is an attractive alternative choice and a safer vaccination strategy against pathogens.

KEYWORDS:

DNA; Lactococcus lactis; Vaccines

PMID:
29090064
PMCID:
PMC5650732

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center